Global Thrombolysis Market Size, Share & Trends Analysis Report by Drug Types (Fibrin Specific Drug and Non-Fibrin Specific Drug), by Application (Deep Vein Thrombosis, Acute Ischemic Strokes, Pulmonary Embolism, Acute Myocardial, and Blocked Catheters), and by End-User(Hospitals and Ambulatory Surgical Centers) Forecast Period (2022-2028)
The global thrombolysis market is anticipated to grow at a substantial CAGR of 5.9% during the forecast period. Thrombolysis is a therapeutic therapy to treat the clots in the blot vessel and improve blood flow to prevent damage to tissue and organs. The blood clot may be dissolved using drugs delivered through a catheter (tube) into the clot. It is used for blocked arteries of the brain, heart, lung, and leg. The increasing prevalence of heart attacks and obesity is propelling the global thrombolysis market. Cardiovascular diseases (CVDs) are the leading cause of death globally. According to the WHO, An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Out of these deaths, 85% were due to heart attack and stroke. Key factors which increase CVD are tobacco use, unhealthy diet and obesity, physical inactivity, and harmful use of alcohol.
The global thrombolysis market is segmented based on drug types, applications, and end-users. Based on drug types, the market is segmented into fibrin-specific drugs and non- fibrin specific drugs. Based on application, the market is bifurcated into deep vein thrombosis, acute ischemic strokes, pulmonary embolism, acute myocardial, and blocked catheters. Based on end-users, the market is segmented into hospitals and ambulatory surgical centers. Among the end-users, the hospitals & clinics segment is expected to grow at a significant CAGR over the forecast period owing to the availability of highly developed infrastructure along with efficient and effective medical equipment in hospitals. Moreover, the rising number of surgeries conducted within the hospitals is higher compared in diagnostic and imaging centers.
Geographically the global thrombolysis market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Among these regions, North America is anticipated to hold a prominent market share across the globe, due to the rising prevalence of blood clots/ VTE, and DVT within the region. It is a medical condition that occurs when a blood clot forms in a deep vein. These clots usually develop in the lower leg, thigh, or pelvis, but they can also occur in the arm. According to CDC, 100,000 people die each year due to blood clots, and VTE affects as many as 900,000 Americans each year. These factors significantly contribute to the growth of the global thrombolysis market.
The major companies serving the global thrombolysis market are Genentech, Microbix, F. Hoffmann-La Roche Ltd., Livzon Diagnostics, Mochida Pharmaceutical Co., Ltd., and Others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, Andera Partners supports TargED Biopharmaceuticals in $41.3 million Series A financing to bring groundbreaking thrombolytic treatment to patients
The market study of the global thrombolysis market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
- Global Thrombolysis Market Research and Analysis by Drug Types.
- Global Thrombolysis Market Research and Analysis by Application.
- Global Thrombolysis Market Research and Analysis by End-User.
The Report Covers
- Comprehensive research methodology of the global thrombolysis market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global thrombolysis market.
- Insights about market determinants that are stimulating the global thrombolysis market.
- Detailed and extensive market segments with the regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global ThrombolysisMarket
- Recovery Scenario of Global ThrombolysisMarket
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
18.104.22.168. Financial Analysis
22.214.171.124. SWOT Analysis
126.96.36.199. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4.1.1. Fibrin Specific Drug
4.1.2. Non- Fibrin Specific Drug
4.2. Global ThrombolysisMarket by Application
4.2.1. Deep Vein Thrombosis
4.2.2. Acute Ischemic Strokes
4.2.3. Pulmonary Embolism
4.2.4. Acute Myocardial
4.2.5. Blocked Catheters
4.3. Global ThrombolysisMarket by End-User
4.3.2. Ambulatory Surgical Centres
5.2.6. Rest of Europe
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6.2. Angiodynamics, Inc.
6.3. Argon Medical Devices Inc.
6.4. Athersys, Inc.
6.5. Bayer Ag
6.6. Boehringer Ingelheim Gmbh
6.7. Boston Scientific Corporation
6.8. Bristol-Myers Squibb
6.9. BTG PLC
6.10. EKOS Corp.
6.11. Genentech Inc.
6.12. GlaxoSmithKline Plc
6.13. Ivascular S.L.U
6.14. Lemaitre Vascular, Inc.
6.15. Medtronic Plc
6.16. Microbix Biosystems Inc.
6.17. Penumbra Inc
6.18. Portola Pharmaceuticals, Inc.
6.19. South Egypt Drug Industries Co.
6.20. Straub Medical Ag
6.21. Teleflex Inc.
6.22. Teva Pharmaceutical Industries Ltd.
A selection of companies mentioned in this report includes:
- Angiodynamics, Inc.
- Argon Medical Devices Inc.
- Athersys, Inc.
- Bayer Ag
- Boehringer Ingelheim Gmbh
- Boston Scientific Corporation
- Bristol-Myers Squibb
- BTG PLC
- EKOS Corp.
- Genentech Inc.
- GlaxoSmithKline Plc
- Ivascular S.L.U
- Lemaitre Vascular, Inc.
- Medtronic Plc
- Microbix Biosystems Inc.
- Penumbra Inc
- Portola Pharmaceuticals, Inc.
- South Egypt Drug Industries Co.
- Straub Medical Ag
- Teleflex Inc.
- Teva Pharmaceutical Industries Ltd.